Sign In
Buy NOVN
$0.0941
+0 (+0%)
At Close: Nov 20, 2023
Is iShares International Equity Factor ETF (INTF) a Strong ETF Right Now?
11:20am, Monday, 23'rd Jan 2023 Zacks Investment Research
Smart Beta ETF report for INTF
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
01:05pm, Wednesday, 18'th Jan 2023 GlobeNewswire Inc.
Live video webcast on Thursday, January 19th at 12:00 PM ET Live video webcast on Thursday, January 19th at 12:00 PM ET
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
08:05am, Wednesday, 18'th Jan 2023
Live video webcast on Thursday, January 19th at 12:00 PM ET Live video webcast on Thursday, January 19th at 12:00 PM ET
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
01:00pm, Friday, 06'th Jan 2023 GlobeNewswire Inc.
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines –
SAN DIEGO--( BUSINESS WIRE )--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and D
Is WisdomTree International Hedged Quality Dividend Growth ETF (IHDG) a Strong ETF Right Now?
11:20am, Tuesday, 03'rd Jan 2023 Zacks Investment Research
Smart Beta ETF report for IHDG
Is WisdomTree International High Dividend ETF (DTH) a Strong ETF Right Now?
11:20am, Wednesday, 28'th Dec 2022 Zacks Investment Research
Smart Beta ETF report for DTH
Is Vanguard International Dividend Appreciation ETF (VIGI) a Strong ETF Right Now?
11:20am, Tuesday, 27'th Dec 2022 Zacks Investment Research
Smart Beta ETF report for VIGI
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
03:00pm, Tuesday, 13'th Dec 2022 GlobeNewswire Inc.
Basel, December 13, 2022 — Novartis today announced detailed results from the pivotal Phase III APPLY-PNH trial1. The results showed a vast majority of patients with paroxysmal nocturnal hemoglobinu
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
06:15am, Thursday, 08'th Dec 2022 GlobeNewswire Inc.
Basel, December 8, 2022 — Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 thera
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
06:30pm, Tuesday, 06'th Dec 2022 GlobeNewswire Inc.
Basel, December 6, 2022 — Novartis today announced results from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in
Novartis prostate cancer drug trial meets primary endpoint
06:44am, Monday, 05'th Dec 2022 MarketWatch
The data will be submitted for regulatory approval next year to the U.S. Food and Drug Administration , Novartis said.
Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
06:15am, Monday, 05'th Dec 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
01:00pm, Friday, 02'nd Dec 2022 GlobeNewswire Inc.
– Agreement provides immediate access to cash flow –
